---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-030025"
form_type: "8-K"
ticker: "NXTC"
cik: "0001661059"
company_name: "NextCure, Inc."
filed_at: "2022-03-03T23:59:59+00:00"
generated_at: "2026-06-27T02:02:15.817277+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# NextCure reports FY 2021 net loss of $69.4M; cash $219.6M, expects funding into Q1 2024

## Summary
- Net loss $69.4M in 2021 vs $36.6M in 2020; no revenue recognized (Eli Lilly agreement ended).
- Cash, equivalents, marketable securities $219.6M at Dec 31, 2021, down $63.8M; expected to fund ops into Q1 2024.
- R&D expenses $50.2M in 2021 vs $46.6M; G&A $20.6M vs $17.0M primarily from headcount increases.
- Multiple 2022 data readouts planned: NC318 Phase 2 update Q4, NC410 update H2, NC762 initial Phase 1 data H2, NC525 IND filing Q4.
- COVID-19 pandemic delayed clinical trial enrollment, causing some milestones to be pushed back.

## SEC filing metadata
- accession: 0001104659-22-030025
- form_type: 8-K
- ticker: NXTC
- cik: 0001661059
- company_name: NextCure, Inc.
- filed_at: 2022-03-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661059/000110465922030025/0001104659-22-030025-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661059/000110465922030025/tm228329d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-030025
- JSON: https://secwatch.observer/filing/0001104659-22-030025.json
- Plain text: https://secwatch.observer/filing/0001104659-22-030025.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.